Evidence map›Paper›PMID 39104771›Full record

ArticleJAC-antimicrobial resistance2024

Promoting antifungal stewardship through an antifungal multidisciplinary team in a paediatric and adult tertiary centre in the UK.

Shuchita Soni, David Hettle, Stephanie Hutchings, Susan Wade, Kate Forrest-Jones, Iara Sequeiros, Andrew Borman, Elizabeth M Johnson, Irasha Harding

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuchita SoniDepartment of Microbiology, University Hospitals Bristol and Weston NHS Trust, Marlborough Street, Bristol BS1 3NU, UK.
David HettleDepartment of Microbiology, University Hospitals Bristol and Weston NHS Trust, Marlborough Street, Bristol BS1 3NU, UK.ORCID https://orcid.org/0000-0002-7606-986X
Stephanie HutchingsUnited Kingdom Health Security Agency (UKHSA) South-West Regional Laboratory, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
Susan WadePharmacy Department, University Hospitals Bristol and Weston NHS Trust, Marlborough Street, Bristol BS1 3NU, UK.
Kate Forrest-JonesPharmacy Department, University Hospitals Bristol and Weston NHS Trust, Marlborough Street, Bristol BS1 3NU, UK.
Iara SequeirosDepartment of Radiology, University Hospitals Bristol and Weston NHS Trust, Marlborough Street, Bristol BS1 3NU, UK.
Andrew BormanUK National Mycology Reference Laboratory, National Infection Service, United Kingdom Health Security Agency South-West, Bristol BS10 5NB, UK.
Elizabeth M JohnsonUK National Mycology Reference Laboratory, National Infection Service, United Kingdom Health Security Agency South-West, Bristol BS10 5NB, UK.
Irasha HardingDepartment of Microbiology, University Hospitals Bristol and Weston NHS Trust, Marlborough Street, Bristol BS1 3NU, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Invasive fungal infections (IFIs) present significant challenges, especially among immunocompromised patients, with associated high morbidity, mortality and significant economic impact. Diagnostic difficulties and the emergence of antifungal resistance necessitates enhanced antifungal stewardship (AFS) efforts. Methods: We report outcomes from a review of our multidisciplinary approach to AFS, based in a 1300-bed teaching hospital in the South-West of England. Retrospectively reviewing all adult and paediatric cases over 12 months in 2022, we investigated demographics, diagnosis, antifungal therapy and adherence to AFS advice, including clinical, mycological, financial and teamwork metrics. Data were extracted from our AFS database, supported by pharmacy records. Results: The AFS multidisciplinary team (MDT) reviewed 111 patients, with 30 day and 1 year mortality of 22.7% and 35.4%, respectively. IFIs classified as proven accounted for 26%, with fungal pathogens identified in 36.3% of cases. Antifungal consumption (by 25.1%) and expenditure (by 59.9%) decreased from 2018 to 2022. The AFS MDT issued 324 recommendations, with a 93% acceptance rate. Conclusions: Our approach to AFS, centred around a weekly MDT, demonstrated improvements in IFI management, antifungal consumption and cost-efficiency. This single-centre study highlights the value of a comprehensive, collaborative approach to AFS involving experts in mycology, infection, radiology, antifungal therapies and clinical teams. The programme's success in paediatric and adult populations and the near-universal acceptance of its recommendations show its potential as a model for replication. It represents a model for enhancing patient care and AFS practices, with future directions aimed at expanding service reach and the integration of further rapid diagnostic modalities.

Identifiers

PMID39104771
PMCPMC11299947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.